APPROVAL OF UNAUDITED FINANCIAL RESULTS OF THE COMPANY FOR THE QUARTER ENDED 30TH JUNE 2026

Zenfabs Tthica Lttr, CIN NO. : L74900CH1993PLC033112, GSTIN NO. : 03AAFCS6226G1ZL Regd. Office; Plot No. 191-195, 3rd Floor, IndustrialArea, Phase-ll, Chandigarh -160 002 Tel. : 0172465 11 05. Fax : 0172-265 6855 E-mail: queries@zenlabsethica.com, Website : www.zenlabsethica.com The Manager Date: August 12,2026 Department of Corporate Services BSE Limited Phiroze Jeejeebhoy Towers Dalal Street, Mumbai-400001 Maharashtra Quarter ended 30u'June 2026. Reft Zenlabs Ethica Limited (Scrip Code: 530697) Dear Madam/Sir, Pursuant to the provisions of Regulation 33 read with Regulation 30 and other applicable provisions of the Securities and Exchange Board of India [Listing Obligations and Disclosure Requirements) Regulatiqns 2015, we wish to inform you that the Board of Directors of the Company had at its meeting held today on Wednesday, August 72,2026, at 3:30 P.M. and following: concluded at 5:00 P.M., inter alia, considered and approved the 1,. The Un-Audited Financial Results for the Quarter ended 30th June, 2026 as per Regulation 33 of SEBI [LODR), 201.5. The Limited Review Report for the quarter ended 30tt'June, 2026. The aforesaid documents are also being disseminated on company's website at wvvw.z e nlab sethi ca. co m. You are requested to kindly take the same on your record, ThankingYou, Yours Truly, FoT ZENLABS ETHICA LIMITED NIKUNJ GOEL COMPANY SECRETARY & COMPLIANCE OFFICER Admin Office : Near Manndt Enclave & Jaharuir Goga Ji Mandir, Khata No. 71gng6, Vitlage Pabhat, Zirakpur, Distt. Mohali-l40603 ZENLABS ETHICA LIMITED Corporate Identification Number L74900CH1993PLC033112, GSTIN 03AAFCS6226G1ZL Registered Office: Plot No. 194-195, 3rd Floor, Industrial Area, Phase II, Chandigarh - 160 002 Telephone 0172-465 1105, Fax: 0172-265 6855 E-mail: queries@zenlabsethica.com, Website: www.zenlabsethica.com E-mail: queries@zenlabsethica.com, Website: www.zenlabsethica.com Statement of unaudited financial results for the quarter ended 30th June, 2026 Quarter Ended Year ended 30-06-2026 31-03-2026 30-06-2025 31-03-2026 (Unaudited) (Refer Note 5) (Unaudited) (Audited) 1. Revenue from operations 1,417.66 1 ,058.41 1 ,147.72 4 ,692.25 2. Other Income 0.06 1 1.60 0 .43 1 8.41 3. Total Income (1+2) 1 ,417.72 1 ,070.00 1 ,148.15 4 ,710.66 4. Expenditure a) Purchase of stock-in-trade 877.54 9 12.22 1 ,012.26 3 ,590.66 b) (Increase)/ decrease in stock-in-trade 475.94 ( 212.36) ( 183.01) ( 191.02) c) Employees benefit expenses 45.21 1 05.83 1 04.11 4 17.22 d) Finance costs 15.70 1 8.29 2 0.76 8 1.02 e) Depreciation and amortisation 10.84 1 3.53 2 9.45 8 9.41 f) Other expenditure 48.06 2 24.60 1 60.12 6 96.87 Total Expenses 1 ,473.28 1 ,062.11 1 ,143.71 4 ,684.16 5. Profit before Exceptional Items (3-4) ( 55.55) 7 .89 4 .45 2 6.50 6. Exceptional Items - - - 2 07.81 7. Profit Before Tax (5-6) ( 55.55) 7 .89 4 .45 ( 181.31) 8. Tax Expenses a) Current and previous year taxes - 7 .96 0 .38 1 0.35 b) Deferred tax 1.56 ( 0.18) 0 .74 1 .90 9. Profit(+)/ Loss(-) for the period (7-8) ( 57.12) 0 .11 3 .33 ( 193.56) 10. Other Comprehensive Income Items that will not be reclassified to profit or loss Re-measurement of the net defined benefit plans 0.80 0 .31 ( 1.63) 3 .34 Tax on above ( 0.20) ( 0.08) 0 .41 ( 0.84) 11. Total Other comprehensive Income, net of tax 0 .60 0 .23 ( 1.22) 2 .50 12. Total comprehensive Income for the period ( 56.52) 0 .34 2 .11 ( 191.06) 13. Paid up equity share capital (Face Value of ₹ 10/- each per share) 6 51.00 6 51.00 6 51.00 6 51.00 14. Other Equity 2 00.43 15. Basic and diluted Earning Per Share (EPS) after Extra Ordinary Items - Basic (in ₹) ( 0.88) 0 .00 0 .05 ( 2.97) - Diluted (in ₹) ( 0.88) 0 .00 0 .05 ( 2.97) NOTES : 1. Theabovefinancialresultsforthequarterended30thJune,2026havebeenreviewedbytheAuditCommitteeandwereapprovedandtakenonrecord bytheBoardofDirectorsintheirrespectivemeetingheldon12thAugust,2026.ThestatutoryauditorsoftheCompanyhaveexpressedanunmodified opinion in audit report on these on these financial results. 2. ThefinancialresultsarepreparedinaccordancewithIndianAccountingStandards(“IndAS”),theprovisionsoftheCompaniesAct,2013(“theAct”), asapplicableandguidelinesissuedbytheSecuritiesandExchangeBoardofIndia(“SEBI”).TheIndASareprescribedunderSection133oftheAct read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 (as amended). 3. TheCompanyisconsideredtobeasinglesegmentcompanyengagedinthetradingofpharmaceuticalsformulation.Consequently,theCompanyhas,in its primary segment, only one reportable business segment. Accordingly, there are no separate reportable segments as required under Ind AS 108 “Operating Segment”. 4. Previous period figures have been re-grouped/ re-classified, wherever necessary, to conform to current period’s classifications. 5. Thefiguresofthelastquarterarethebalancingfiguresbetweentheauditedfiguresinrespectoffullyearandtheunauditedpublishedfiguresuptothe third quarter ended December 31, 2025 which were subjected to review. for and on behlaf of Board of Directors Sanjay Dhir Place: Chandigarh Whole Time Director Date: 12th August , 2026 DIN: 02452461